The British government's medicines advisory body has advised against the use of GlaxoSmithKline's oral cancer drug Tyverb in the National Health Service. The National Institute of Health and Clinical Excellence (Nice) have recommended that Tyverb (used to treat advanced breast cancer) does not meet its threshold for clinical and cost effectiveness.

Full article